Company Description
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases.
Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer.
The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH.
The company was incorporated in 2013 and is based in Pudong, China.
| Country | China |
| Founded | 2013 |
| IPO Date | Sep 20, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,784 |
| CEO | Ying Du |
Contact Details
Address: Building B, 899 Halei Road Pudong, 201203 China | |
| Phone | 86 21 6163 2588 |
| Website | zailaboratory.com |
Stock Details
| Ticker Symbol | ZLAB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001704292 |
| CUSIP Number | 98887Q104 |
| ISIN Number | US98887Q1040 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Du Ph.D. | Founder, Chairperson and Chief Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 21, 2026 | 8-K | Current Report |
| May 18, 2026 | 144 | Filing |
| May 15, 2026 | 144 | Filing |
| May 14, 2026 | 144 | Filing |
| May 14, 2026 | 144 | Filing |
| May 13, 2026 | 144 | Filing |
| May 7, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | 8-K | Current Report |
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |